Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?

Basit Öğe Kaydı
dc.authorid0000-0002-4600-1290
dc.authorid0000-0002-0598-7284
dc.authorid0000-0003-3229-830X
dc.authorid0000-0003-0804-2654
dc.authorid0000-0002-1030-5049
dc.authorid0000-0002-0549-9969
dc.authorid0000-0001-5686-4121
dc.contributor.authorKılıçgün, Ali
dc.contributor.authorTanrıverdi, Özgür
dc.contributor.authorTurna, Akif
dc.contributor.authorMetin, Muzaffer
dc.contributor.authorSayar, Adnan
dc.contributor.authorSolak, Okan
dc.contributor.authorÜrer, Nur
dc.contributor.authorGürses, Atilla
dc.date.accessioned2021-06-23T18:56:20Z
dc.date.available2021-06-23T18:56:20Z
dc.date.issued2012
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractIn the 1997 revision of the TNM staging system for lung cancer, patients with T3N0M0 disease were moved from stage IIIA to stage IIB since these patients have a better prognosis. Despite this modification, the local lymph node metastasis remained the most important prognostic factor in patients with lung cancer. The present study aimed to evaluate the prognosis of patients with T3N1 disease as compared with that of patients with stages IIIA and IIB disease. During 7-year period, 313 patients with non-small cell lung cancer (297 men, 16 women) who had resection were enrolled. The patients were staged according the 2007 revision of Lung Cancer Staging by American Joint Committee on Cancer. The Kaplan-Meier statistics was used for survival analysis, and comparisons were made using Cox proportional hazard method. The 5-year survival of patients with stage IIIA disease excluding T3N1 patients was 40%, whereas the survival of the patients with stage IIB disease was 66% at 5 years. The 5-year survival rates of stage III T3N1 patients (singlestation N1) was found to be higher than those of patients with stage IIIA disease (excluding pT3N1 patients, P = 0.04), while those were found to be similar with those of patients with stage IIB disease (P = 0.4). Survival of the present cohort of patients with T3N1M0 disease represented the survival of IIB disease rather than IIIA non-small cell lung cancer. Further studies are needed to suggest further revisions in the recent staging system regarding T3N1MO disease.en_US
dc.identifier.doi10.1007/s12032-011-9907-y
dc.identifier.endpage613en_US
dc.identifier.issn1357-0560
dc.identifier.issue2en_US
dc.identifier.pmid21431959en_US
dc.identifier.scopus2-s2.0-84866291482en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage607en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-011-9907-y
dc.identifier.urihttps://hdl.handle.net/20.500.12491/4983
dc.identifier.urihttps://link.springer.com/content/pdf/10.1007/s12032-011-9907-y
dc.identifier.volume29en_US
dc.identifier.wosWOS:000303539000033en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçgün, Ali
dc.language.isoenen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCarcinomaen_US
dc.subjectLung Canceren_US
dc.subjectLymphatic Metastasisen_US
dc.subjectNeoplasm Stagingen_US
dc.subjectNon-small Cellen_US
dc.subjectSurvivalen_US
dc.titlePrognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
ali-kılıcgun.pdf
Boyut:
194.57 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu